https://novapharmanews.com/whitepapers 2026-05-05T03:30:36.057Z daily 0.8 https://novapharmanews.com/whitepapers/strategies-to-enhance-recruitment-of-female-participants-to-cardiovascular-resea-34f28465 2026-05-05T02:08:42.595Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/34f2846537a747339e930e1660533c921455e287e6eb64eeac6db0c3bdfd8070.webp Strategies to Enhance Recruitment of Female Participants to Cardiovascular Research https://novapharmanews.com/whitepapers/british-society-of-gastroenterology-guidelines-on-inflammatory-bowel-disease-in-bb9a5453 2026-05-05T02:40:41.230Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/bb9a5453931618a1d5ac761bdd99389daee8a074a3ba2d71970b12678b952e03.webp British Society of Gastroenterology Guidelines on Inflammatory Bowel Disease in Adults: 2025 https://novapharmanews.com/whitepapers/barriers-and-facilitators-to-use-of-digital-health-tools-by-healthcare-practitio-8aa8f7a1 2026-05-05T03:18:35.246Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/8aa8f7a1c904fa25a87042db68584de886365d35ebd59c004033e9dca3e23b6a.webp Barriers and Facilitators to Use of Digital Health Tools by Healthcare Practitioners https://novapharmanews.com/whitepapers/the-patient-confusion-crisis-ffbe8f47 2026-05-05T02:11:54.206Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/ffbe8f47175d98da99c95a2ac5eea3979df6a3584e7b352a5bb180729c57f37d.webp The Patient Confusion Crisis https://novapharmanews.com/whitepapers/cigna-medical-coverage-policy-acupuncture-54ad08a4 2026-05-05T01:53:14.908Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/54ad08a4f01dbe89cd49fed73d30a0a8d5a06dc5d03e249eeaa809c5769572ff.webp Cigna Medical Coverage Policy: Acupuncture https://novapharmanews.com/whitepapers/ai-biologics-design-chai-discovery-eli-lilly-partnership-b2de5695 2026-05-05T02:35:07.312Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/b2de5695d5b998dab25fb692ce4e86848c2f86517811713aa57c49de96433d86.webp AI Biologics Design: Chai Discovery & Eli Lilly Partnership https://novapharmanews.com/whitepapers/patient-mastering-as-enterprise-infrastructure-fe80a425 2026-05-05T02:06:02.957Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/fe80a425a9219e3fb2e4e919de44b44d73256c0fa383643bf2761aa1a8374f99.webp Patient Mastering as Enterprise Infrastructure https://novapharmanews.com/whitepapers/la-negoziazione-del-prezzo-dei-farmaci-oncologici-in-italia-9b66aaec 2026-05-05T03:18:59.527Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/9b66aaeca90ef3d69faf0f6b8d4b9c8e7a061722c62f0352abc99fecb2124a30.webp La Negoziazione del Prezzo dei Farmaci Oncologici in Italia https://novapharmanews.com/whitepapers/from-automotive-to-medtech-proven-software-development-practices-3c7b9865 2026-05-05T02:34:27.679Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/3c7b9865b4be3e89efb740a949f4a3813c76c54872353eab8cc784af5a94e326.webp From Automotive to MedTech: Proven Software Development Practices https://novapharmanews.com/whitepapers/agentic-ai-in-pharma-merck-google-cloud-1b-partnership-75d87cd5 2026-05-05T02:08:52.787Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/75d87cd5c99d6960797d4990492a22fe326fc85cedc9f642bfe5f5d96284d285.webp Agentic AI in Pharma: Merck & Google Cloud $1B Partnership https://novapharmanews.com/whitepapers/ensuring-compatibility-for-glp-1-based-drugs-31f1b6e3 2026-05-05T02:36:40.479Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/31f1b6e39e363eb03de4e9e0d1e37c49b0d896179ad25fefc70a2bcc4c91d289.webp Ensuring Compatibility for GLP-1-based Drugs https://novapharmanews.com/whitepapers/lilly-s-weight-loss-pill-approved-sparking-competition-with-novo-nordisk-0996e5f8 2026-05-05T02:36:44.067Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/0996e5f864e163989a66f3490da19d19b3b64330a8eafe8c567ee3617a811c7f.webp Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk https://novapharmanews.com/whitepapers/medicare-risk-arrangement-and-use-and-outcomes-among-physician-groups-5d1f430b 2026-05-05T02:32:26.417Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/5d1f430b04a0b0b19434d5c9c9917a7d4488b06104b8f1789a548239fed74437.webp Medicare Risk Arrangement and Use and Outcomes Among Physician Groups https://novapharmanews.com/whitepapers/agentic-ai-for-pharma-launches-access-engagement-3dbadb95 2026-05-04T23:56:06.910Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/3dbadb95fed0e40904e42b995fd1327f3a06f096babad22231c6d2786eec22b4.webp Agentic AI for Pharma Launches: Access & Engagement https://novapharmanews.com/whitepapers/radiation-therapy-fractionation-image-guidance-and-special-services-idaho-only-cd473ccf 2026-05-05T03:21:26.766Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/cd473ccf068ddfb152cca633ddc900ada9edde6f954e495e7b44342c462526bd.webp Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) https://novapharmanews.com/whitepapers/clinical-appropriateness-guidelines-for-imaging-of-the-chest-2e352068 2026-05-05T03:12:31.437Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/2e3520683ce58e59a59c1e9cd62f353bb399008a850b46740f1d9ef6060d01fb.webp Clinical Appropriateness Guidelines for Imaging of the Chest https://novapharmanews.com/whitepapers/drug-testing-for-substance-use-and-pain-management-640851a4 2026-05-05T02:10:22.913Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/640851a4a68b300c94d946ff06638fada10d7279126465a13a83a6a66cbc501f.webp Drug Testing for Substance Use and Pain Management https://novapharmanews.com/whitepapers/global-health-in-the-age-of-ai-c6847a4d 2026-05-05T01:48:47.362Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/c6847a4d1b8d100e18ef2e1c87b26872c0537992cd5be55fe79240148facdaed.webp Global Health in the Age of AI https://novapharmanews.com/whitepapers/transform-downstream-processing-with-an-integrated-solution-630e49be 2026-05-05T01:40:11.292Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/630e49beb8ee6093dd5ba3f7dc817feb95e622d5de1c662c0fdc747a28c493a3.webp Transform Downstream Processing with an Integrated Solution https://novapharmanews.com/whitepapers/examining-the-validity-of-external-controls-relative-to-randomized-controls-448b0379 2026-05-05T02:41:42.532Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/448b0379665279b35c4fab685c0e081ea0f26bd2e9c4c19740fd626bf6a336fd.webp Examining the Validity of External Controls Relative to Randomized Controls https://novapharmanews.com/whitepapers/fda-draft-guidance-on-ai-in-drug-development-explained-40e99669 2026-05-05T02:10:09.352Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/40e99669049c24fe5357efbac70a6367a69f5753d8987d7ba65f754050a02338.webp FDA Draft Guidance on AI in Drug Development Explained https://novapharmanews.com/whitepapers/a-dataset-of-digital-therapeutic-device-approvals-to-support-regulatory-decision-d0cb7dfe 2026-05-05T01:11:41.252Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/d0cb7dfeee93ac6d84c55e3a281d96c360cb4e1ca33ea0383b32abd09911b8a0.webp A dataset of digital therapeutic device approvals to support regulatory decisions and industry research https://novapharmanews.com/whitepapers/radiopharmaceuticals-eu-in-horizon-scanning-report-b232fb2b 2026-05-04T23:16:32.105Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/b232fb2ba236d637fe9a56cf924dec44f07e02aa731b6b52cae97c25f64c05b9.webp Radiopharmaceuticals - EU-IN Horizon Scanning Report https://novapharmanews.com/whitepapers/cytological-specimens-in-the-molecular-era-of-metastatic-melanoma-7bb19087 2026-05-05T01:30:37.426Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/7bb190871df8ebb00e5e911a09a8df7db325123378e9cfe10a52a0119fe68112.webp Cytological Specimens in the Molecular Era of Metastatic Melanoma https://novapharmanews.com/whitepapers/ashp-policy-positions-1982-2026-97668586 2026-05-05T01:10:29.105Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/97668586fe09fe175492a272af3408b6ea7fb63e4ab798892a40ee248402a3c1.webp ASHP Policy Positions 1982-2026 https://novapharmanews.com/whitepapers/announcement-of-calendar-year-cy-2027-medicare-advantage-ma-capitation-rates-and-8bb37a09 2026-05-05T03:19:24.843Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/8bb37a0969062c57600f5cea9a0f2f281ee1377d91444afc36554f58ad0d8504.webp Announcement of Calendar Year (CY) 2027 Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies https://novapharmanews.com/whitepapers/the-2024-eu-gmp-annex-1-revision-a-technical-roadmap-for-holistic-contamination-46398984 2026-05-05T01:29:53.855Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/46398984f509a17a179ded856996523bfa4128e75f64f7d2f78e05d7d07bb0c5.webp The 2024 EU GMP Annex 1 Revision: A Technical Roadmap for Holistic Contamination Control and Quality Risk Management in Sterile Manufacturing https://novapharmanews.com/whitepapers/scientific-standards-for-23andme-s-health-and-trait-reports-88550674 2026-05-05T01:15:54.603Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/885506743fcd48c0175a6ea1faf4fb27a13f96418fd9857c723311bcf9238829.webp Scientific Standards for 23andMe's Health and Trait Reports https://novapharmanews.com/whitepapers/european-medicines-agency-pre-authorisation-procedural-advice-4dff446d 2026-05-05T00:32:23.547Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/4dff446df529f112567b54a4b81896db40171b025f055e25c00ac73d37a7c8bd.webp European Medicines Agency Pre-Authorisation Procedural Advice https://novapharmanews.com/whitepapers/aesgp-position-on-commission-proposal-for-simplification-of-mdr-8d60b6d6 2026-05-05T01:18:29.226Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/8d60b6d6c1b9eb9225a7e3dcdc51e4f2c0fa007a3bb082105a6f964818cf5beb.webp AESGP Position on Commission Proposal for Simplification of MDR https://novapharmanews.com/whitepapers/futureproofing-post-approval-compliance-by-integrating-lqppv-and-lifecycle-manag-b43fe204 2026-05-05T01:28:49.935Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/b43fe2047b24d5b6c99eff72ee1f1c252faf022d830dfef5cf67406b93b69d22.webp Futureproofing Post Approval Compliance by Integrating LQPPV and Lifecycle Management with Applied AI https://novapharmanews.com/whitepapers/overview-of-comments-received-on-ich-q3e-guideline-efb681c3 2026-05-05T00:21:25.475Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/efb681c3adab2796a6c04e63618223b88b7bc21ddadbf7684bbbb1a68670fe0a.webp Overview of Comments Received on ICH Q3E Guideline https://novapharmanews.com/whitepapers/strengthening-the-fda-s-accelerated-approval-pathway-progress-and-unfinished-bus-837fc439 2026-05-05T03:10:52.235Z monthly 0.7 https://novapharmanews.com/uploads/whitepapers/thumbs/837fc4396176b0738cc5cef05b5f42649a9ea2140dc3127b3581fd2d1bb1107a.webp Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business